Retevmo
Retevmo ingredients
| Active ingredient | Strength |
|---|---|
| Selpercatinib | 40 mg/1, 80 mg/1, 160 mg/1, 120 mg/1 |
What Retevmo is used for
The FDA lists the approved uses on the official label (below). In the EU, selpercatinib is approved as Retsevmo for:
Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. For biomarker-based patient selection, see section 4.2. Retsevmo as monotherapy is indicated for the treatment of adults and paediatric patients 2 years of age and older with: advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) . For biomarker-based patient selection, see section 4.2. advanced RET mutant medullary thyroid cancer (MTC) . For biomarker-based patient selection, see section 4.2. advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1). For biomarker-based patient selection, see section 4.2.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Retevmo
- Generic name
- Selpercatinib
- Made by
- Eli Lilly and Company
- Forms
- Capsule, Tablet, Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA218160
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Selpercatinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Retevmo?
Retevmo (Selpercatinib) is a cancer medicine made by Eli Lilly and Company, approved by the US FDA.
What are the ingredients of Retevmo?
Retevmo contains Selpercatinib (40 mg/1, 80 mg/1, 160 mg/1, 120 mg/1).
Is Retevmo approved in Europe?
The same active substance is approved in the EU as Retsevmo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA